AR124589A1 - Métodos y compuestos para tratar la ataxia de friedreich - Google Patents

Métodos y compuestos para tratar la ataxia de friedreich

Info

Publication number
AR124589A1
AR124589A1 ARP220100032A ARP220100032A AR124589A1 AR 124589 A1 AR124589 A1 AR 124589A1 AR P220100032 A ARP220100032 A AR P220100032A AR P220100032 A ARP220100032 A AR P220100032A AR 124589 A1 AR124589 A1 AR 124589A1
Authority
AR
Argentina
Prior art keywords
terminus
alkyl
optionally substituted
hydrogen
independently
Prior art date
Application number
ARP220100032A
Other languages
English (en)
Spanish (es)
Inventor
Aseem Ansari
Abhi Bhat
Sean Jeffries
Pratik Shah
Chengzhi Zhang
Original Assignee
Design Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Design Therapeutics Inc filed Critical Design Therapeutics Inc
Publication of AR124589A1 publication Critical patent/AR124589A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
ARP220100032A 2021-01-08 2022-01-07 Métodos y compuestos para tratar la ataxia de friedreich AR124589A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163135427P 2021-01-08 2021-01-08

Publications (1)

Publication Number Publication Date
AR124589A1 true AR124589A1 (es) 2023-04-12

Family

ID=82358799

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100032A AR124589A1 (es) 2021-01-08 2022-01-07 Métodos y compuestos para tratar la ataxia de friedreich

Country Status (11)

Country Link
US (1) US20240124491A1 (https=)
EP (1) EP4274583A4 (https=)
JP (1) JP2024502469A (https=)
CN (1) CN117241805A (https=)
AR (1) AR124589A1 (https=)
AU (1) AU2022206424A1 (https=)
CA (1) CA3204523A1 (https=)
IL (1) IL304322A (https=)
MX (1) MX2023008153A (https=)
TW (1) TW202241892A (https=)
WO (1) WO2022150555A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための方法及び化合物
JP2025502064A (ja) * 2022-01-06 2025-01-24 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための化合物及び方法
CN119708005A (zh) * 2023-09-27 2025-03-28 北京沐华生物科技有限责任公司 一类brd4蛋白降解剂化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270727A1 (en) * 2005-05-03 2006-11-30 Christian Melander Small molecule therapeutics and uses therefor
RU2720237C2 (ru) * 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
US10517877B2 (en) * 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
PT3442972T (pt) * 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
WO2019204781A1 (en) * 2018-04-20 2019-10-24 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease
EP4234550A3 (en) * 2018-05-22 2023-09-06 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease
US20220047596A1 (en) * 2018-09-12 2022-02-17 Board Of Regents, The University Of Texas System Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
CN121045206A (zh) * 2020-02-03 2025-12-02 设计治疗公司 用于治疗遗传疾病的方法和化合物
WO2022126000A1 (en) * 2020-12-11 2022-06-16 Design Therapeutics, Inc. Methods and compounds for modulating myotonic dystrophy 1
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための方法及び化合物

Also Published As

Publication number Publication date
CA3204523A1 (en) 2022-07-14
IL304322A (en) 2023-09-01
MX2023008153A (es) 2023-09-21
TW202241892A (zh) 2022-11-01
AU2022206424A1 (en) 2023-08-24
AU2022206424A9 (en) 2024-09-19
WO2022150555A3 (en) 2022-12-22
CN117241805A (zh) 2023-12-15
JP2024502469A (ja) 2024-01-19
WO2022150555A2 (en) 2022-07-14
US20240124491A1 (en) 2024-04-18
EP4274583A4 (en) 2025-01-22
EP4274583A2 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
AR124589A1 (es) Métodos y compuestos para tratar la ataxia de friedreich
US12146880B2 (en) Artificial transcription factors comprising a sliding domain and uses thereof
US20210403719A1 (en) Rhodamine dyes and conjugates
ES2397973T3 (es) Inhibidores peptidomiméticos del PSMA, compuestos que los comprenden y métodos de utilización
ES2705068T3 (es) Síntesis química y cribado de bibliotecas de péptidos bicíclicos
US8968700B2 (en) Imaging of protease activity in live cells using activity based probes
FR2913424A1 (fr) Derives de cyanine, conjuges fluorescents les contenant et leur utilisation
BR112012031363A2 (pt) Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais.
WO2010045598A2 (en) Psma binding ligand-linker conjugates and methods for using
BRPI0720306A2 (pt) Sistemas de macrociclização da bis-sufidrila
ES2294103T3 (es) Inhibidores de vih proteasa con base en derivados de aminoacidos.
Saidjalolov et al. Inclusive Pattern Generation Protocols to Decode Thiol-Mediated Uptake
US20120251459A1 (en) Specific inhibitors and active site probes for legumain
CO2024010651A2 (es) Compuestos y métodos para tratar la ataxia de friedreich
Zhou et al. Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors
FR2670787A1 (fr) Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
ES2877612T3 (es) Derivados de porfirinas, su procedimiento de preparación y su uso para tratar infecciones virales
JP5393482B2 (ja) 抗癌活性を有するテトラサイクリン・アントラキノン系化合物
ES2385572T3 (es) Nuevos inhibidores duales de peptidasa como promedicamentos para terapia de enfermedades inflamatorias y otras
ES2340376T3 (es) Desproteccion del azufre posterior a la escision para la sintesis convergente de proteinas mediante ligacion quimica.
RU2014141896A (ru) Стабильные пептидные миметики промежуточного продукта предшпильки gp41 вич-1
WO2014016460A1 (es) Compuestos dendríticos carbosilanos homo y hetero-funcionalizados
Okuda-Shinagawa et al. Fluorescent and photosensitizing conjugates of cell-penetrating peptide TAT (47-57): Design, microwave-assisted synthesis at 60 C, and properties
Bang et al. Amphiphilic small peptides for delivery of plasmid DNAs and siRNAs
CN118146289A (zh) 一种正负调控nampt以及nad+的光控protac化合物及其应用